📣 VC round data is live. Check it out!

Convatec Group Valuation Multiples

Discover Convatec Group's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Renishaw, Hamamatsu Photonics, Snibe, Bausch + Lomb and more.

Convatec Group Overview

About Convatec Group

Originally spun out of Bristol-Myers Squibb, Convatec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and ostomy supplies are the largest divisions, accounting for 32% and 28% of total revenue, respectively. Continence care has become a slightly smaller business (22% of revenue) following the decision to exit the acute care market, and infusion sets contribute 18% of consolidated revenue.


Founded

2016

HQ

United Kingdom

Employees

10.5K

Financials (LTM)

Revenue: $2B
EBITDA: $665M

EV

$7B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Convatec Group Financials

Convatec Group reported last 12-month revenue of $2B and EBITDA of $665M.

In the same LTM period, Convatec Group generated $2B in gross profit, $665M in EBITDA, and $374M in net income.

Revenue (LTM)


Convatec Group P&L

In the most recent fiscal year, Convatec Group reported revenue of $2B and EBITDA of $646M.

Convatec Group is profitable as of last fiscal year, with gross margin of 56%, EBITDA margin of 26%, and net margin of 15%.

See analyst estimates for Convatec Group
LTMLast FY202320242025202620272028
Revenue$2B$2B$2B$2B$2B
Gross Profit$2B$1B$1B$1B$1B
Gross Margin60%56%56%56%56%
EBITDA$665M$646M$456M$540M$516M
EBITDA Margin27%26%21%24%21%
EBIT Margin23%22%12%14%16%
Net Profit$374M$358M$130M$191M$175M
Net Margin15%15%6%8%7%
Net Debt-$1B---

Financial data powered by Morningstar, Inc.

Convatec Group Stock Performance

Convatec Group has current market cap of $5B, and enterprise value of $7B.

Market Cap Evolution


Convatec Group's stock price is $2.61.

Convatec Group share price decreased by 4.0% in the last 30 days, and by 32.2% in the last year.

Convatec Group has an EPS (earnings per share) of $0.18.

See more trading valuation data for Convatec Group
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$7B$5B-4.0%-4.0%-10.7%-32.2%$0.18

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Convatec Group Valuation Multiples

Convatec Group trades at 2.6x EV/Revenue multiple, and 9.8x EV/EBITDA.

See NTM and 2027E valuation multiples for Convatec Group

EV / Revenue (LTM)


Convatec Group Financial Valuation Multiples

As of June 4, 2026, Convatec Group has market cap of $5B and EV of $7B.

Convatec Group has a P/E ratio of 13.7x.

LTMLast FY202320242025202620272028
EV/Revenue2.6x2.7x3.1x2.9x2.7x
EV/EBITDA9.8x10.1x14.4x12.1x12.7x
EV/EBIT11.6x12.0x24.7x19.8x17.0x
EV/Gross Profit4.4x4.8x5.5x5.1x4.8x
P/E13.7x14.3x39.2x26.8x29.2x
EV/FCF25.5x23.0x27.5x23.9x23.0x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Convatec Group Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Convatec Group Margins & Growth Rates

Convatec Group grew revenue by 5% and EBITDA by 7% in the last fiscal year.

In the most recent fiscal year, Convatec Group reported gross margin of 56%, EBITDA margin of 26%, and net margin of 15%.

See estimated margins and future growth rates for Convatec Group

Convatec Group Margins

Last FY202420252026202720282029
Gross Margin56%56%56%61%
EBITDA Margin26%24%21%27%
EBIT Margin22%14%16%23%
Net Margin15%8%7%15%
FCF Margin12%12%12%10%

Convatec Group Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth5%7%7%5%
Gross Profit Growth14%7%7%14%
EBITDA Growth7%19%(4%)34%
EBIT Growth8%25%16%53%
Net Profit Growth10%46%(8%)126%
FCF Growth(9%)15%4%(9%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Convatec Group Operational KPIs

Convatec Group's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Convatec Group's Rule of 40 is 32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Convatec Group's Rule of X is 40% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Convatec Group
LTMLast FY202320242025202620272028
Rule of 4033%32%---
Bessemer Rule of X42%40%---
Revenue per Employee-$0.2M---
Opex per Employee-$0.1M---
S&M Expenses to Revenue27%28%29%28%27%
G&A Expenses to Revenue7%8%10%9%8%
R&D Expenses to Revenue4%5%5%5%5%
Opex to Revenue-40%44%42%40%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Convatec Group Competitors

Convatec Group competitors include Renishaw, Hamamatsu Photonics, Snibe, Bausch + Lomb, Andon Health, Getinge, Canon Marketing Japan, Caris Life Sciences, Teleflex and Sysmex.

Most Convatec Group public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Renishaw5.1x4.7x22.8x20.8x
Hamamatsu Photonics3.6x3.5x17.8x17.7x
Snibe7.2x6.9x16.1x15.7x
Bausch + Lomb2.0x1.9x11.4x10.7x
Andon Health25.2x-12.7x-
Getinge1.6x1.6x8.6x8.6x
Canon Marketing Japan0.9x0.9x8.2x8.2x
Caris Life Sciences5.3x4.8x31.0x29.5x

This data is available for Pro users. Sign up to see all Convatec Group competitors and their valuation data.

Start Free Trial

Convatec Group VC Funding History

Before going public, Convatec Group raised $2B in total equity funding, across 2 rounds.

Last private valuation of Convatec Group was $34B, after raising $1B in March 2017 from Novo Holdings.


Convatec Group Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Nov-25Secondary - public-$465M--
Mar-17Secondary - publicNovo Holdings$1B$34BConvaTec is a UK-based global medical products and technologies company focused on advanced wound care, ostomy care, continence and critical care, and infusion devices for diabetes and chronic conditions. Nordic Capital and Avista sold a 19.95% shareholding comprising 389.3 million shares to Novo A/S, the investment holding company of the Novo Nordisk Foundation, at a price of 260 pence per share, valuing the stake at around £1.01 billion and implying a full company valuation of approximately £5.06 billion. The transaction occurred in March 2017, shortly after ConvaTec's IPO in October 2016, with sellers waiving a 180-day lock-up to enable the sale and a concurrent placing of additional shares to institutional investors. Novo A/S acquired the stake for £1.01 billion, gaining the right to appoint one director to the ConvaTec board, nominating CEO Kasim Kutay. The deal validated ConvaTec's strategy and product portfolio in the medical products sector, introducing a long-term healthcare investor. Novo Holdings later fully exited its ConvaTec investment, including selling the remaining ~7.8% stake in 2025 for GBP351 million at 227 pence per share.

Acquisitions by Convatec Group

Convatec Group has acquired 5 companies to date.

Last acquisition by Convatec Group was on April 19th 2023. Convatec Group acquired 30 Technology for $57M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Convatec Group

30 Technology
Triad Life Sciences
J&R Medical
Woodbury Health Products
Description
30 Technology is a biopharmaceutical platform company developing nitric oxide-based therapies for serious medical conditions. Its technology enables new care models enhancing patient healing and immune responses. The firm partners with healthcare providers to advance treatments for cardiovascular and respiratory diseases.
Triad Life Sciences is a San Diego-based biotechnology company advancing regenerative medicine through bioactive extracellular matrix (ECM) biomaterials. Their proprietary ECM platforms support wound healing, orthopedics, and cardiovascular applications, derived from decellularized porcine tissues. With leadership holding patents from companies like Integra LifeSciences, Triad Life Sciences collaborates with UC San Diego for preclinical trials. Launched in 2020, the firm raised Series A funding to scale manufacturing under ISO 13485 standards.
J&R Medical is a nationwide distributor of urological, enteral feeding, incontinence, and ostomy supplies to hospitals, long-term care facilities, and home care patients across the United States. The company offers products from brands like Hollister, Coloplast, and Medline, with direct delivery options and customized ordering for various price points.
Woodbury Health Products is a Wilmington, North Carolina-based distributor of incontinence solutions, operating from its dedicated facility for nearly 35 years. The company supplies absorbent products, protective undergarments, and hygiene aids to individuals, families, and caregivers across the United States, emphasizing discreet and effective management of urinary health issues.
HQ CountryUnited KingdomUnited StatesUnited StatesUnited States
HQ City
-
Memphis, TN
Oklahoma City, OK
New York City, NY
Deal Date19 Apr 202328 Jan 20222 Mar 201820 Jul 2017
Valuation$57M$450M$14M$121M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Convatec Group acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Convatec Group

Convatec Group has invested in 1 company to date.

Latest investment by Convatec Group was on May 9th 2022. Convatec Group invested in BlueWind Medical in their $64M Series B round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Convatec Group

BlueWind Medical
Description
BlueWind Medical is a medtech company marketing the Revi wireless neurostimulation system for chronic peripheral neuropathic pain in the lower limbs. The implantable device delivers on-demand electrical pulses via a coin-sized stimulator placed near the nerve, avoiding bulky hardware. Approved in Europe in 2021, it entered U.S. pivotal trials targeting over 20 million patients. Based in Herzliya, Israel, BlueWind Medical raised $75 million in funding and partners with Boston Scientific for distribution.
HQ CountryIsrael
HQ City
Herzliya
Deal Date9 May 2022
RoundSeries B
Raised$64M
InvestorsConvatec Group
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Convatec Group investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Convatec Group

When was Convatec Group founded?Convatec Group was founded in 2016.
Where is Convatec Group headquartered?Convatec Group is headquartered in United Kingdom.
How many employees does Convatec Group have?As of today, Convatec Group has over 10K employees.
Is Convatec Group publicly listed?Yes, Convatec Group is a public company listed on London Stock Exchange.
What is the stock symbol of Convatec Group?Convatec Group trades under CTEC ticker.
When did Convatec Group go public?Convatec Group went public in 2016.
Who are competitors of Convatec Group?Convatec Group main competitors include Renishaw, Hamamatsu Photonics, Snibe, Bausch + Lomb, Andon Health, Getinge, Canon Marketing Japan, Caris Life Sciences, Teleflex, Sysmex.
What is the current market cap of Convatec Group?Convatec Group's current market cap is $5B.
What is the current revenue of Convatec Group?Convatec Group's last 12 months revenue is $2B.
What is the current revenue growth of Convatec Group?Convatec Group revenue growth (NTM/LTM) is 6%.
What is the current EV/Revenue multiple of Convatec Group?Current revenue multiple of Convatec Group is 2.6x.
What is the current EBITDA of Convatec Group?Convatec Group's last 12 months EBITDA is $665M.
What is Convatec Group's EBITDA margin?Convatec Group's last 12 months EBITDA margin is 27%.
What is the current EV/EBITDA multiple of Convatec Group?Current EBITDA multiple of Convatec Group is 9.8x.
What is the current FCF of Convatec Group?Convatec Group's last 12 months FCF is $257M.
What is Convatec Group's FCF margin?Convatec Group's last 12 months FCF margin is 10%.
What is the current EV/FCF multiple of Convatec Group?Current FCF multiple of Convatec Group is 25.5x.
How many companies Convatec Group has acquired to date?As of June 2026, Convatec Group has acquired 5 companies.
What was the largest acquisition by Convatec Group?$450M acquisition of Triad Life Sciences on 28th January 2022 was the largest M&A Convatec Group has done to date.
What companies Convatec Group acquired?Convatec Group acquired Triad Life Sciences, Woodbury Health Products, 30 Technology, EuroTec, and J&R Medical.
In how many companies Convatec Group has invested to date?As of June 2026, Convatec Group has invested in 1 company.
What was the last Convatec Group investment?On 9th May 2022 Convatec Group invested in BlueWind Medical, participating in a $64M Series B round.
In what companies Convatec Group invested in?Convatec Group invested in BlueWind Medical.

See public comps similar to Convatec Group

Lists including Convatec Group

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial